Overall Survival with Ribociclib plus Endocrine Therapy in Breast CancerSeock‐Ah Im, Debu Tripathy, Marco Colleoni et al.|New England Journal of Medicine|2019Cited by 1k
EP.12H.09 Phase 1b/2a Study of ATR Inhibitor Tuvusertib + Anti-PD-1 Cemiplimab in Patients with Advanced Non-Squamous NSCLCNatalie I. Vokes, L.C. Villaruz, L. Paz-Ares et al.|Journal of Thoracic Oncology|2024Cited by 0